Key Points
- BDX CEO Thomas Polen, Jr. sold 2,764 shares on June 1 at an average price of $146.35, totaling about $404,511. After the sale, he still owned 110,163 shares valued at roughly $16.1 million.
- The sale was disclosed in an SEC filing and was executed under a pre-arranged Rule 10b5-1 trading plan, which can indicate the transaction was planned in advance rather than made on new information.
- Becton, Dickinson recently beat quarterly earnings and revenue estimates and continues to pay a dividend of $1.05 per share, equal to a 2.9% annualized yield. However, analysts currently rate the stock a consensus Hold.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) CEO Thomas Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer directly owned 110,163 shares of the company's stock, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Becton, Dickinson and Company Price Performance
Becton, Dickinson and Company stock opened at $145.52 on Thursday. The stock has a market cap of $40.10 billion, a P/E ratio of 36.84, a price-to-earnings-growth ratio of 10.22 and a beta of 0.22. The company has a fifty day simple moving average of $150.99 and a 200-day simple moving average of $176.01. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.13. The business had revenue of $4.71 billion during the quarter, compared to analysts' expectations of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The company's revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the company earned $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities analysts expect that Becton, Dickinson and Company will post 12.61 EPS for the current fiscal year.
Becton, Dickinson and Company Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be paid a dividend of $1.05 per share. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 annualized dividend and a yield of 2.9%. Becton, Dickinson and Company's payout ratio is presently 106.33%.
Institutional Investors Weigh In On Becton, Dickinson and Company
A number of institutional investors and hedge funds have recently added to or reduced their stakes in BDX. Auto Owners Insurance Co lifted its stake in Becton, Dickinson and Company by 22,225.2% in the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier's stock valued at $790,079,000 after buying an additional 40,528,680 shares during the last quarter. Wellington Management Group LLP lifted its stake in Becton, Dickinson and Company by 9,056.3% in the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier's stock valued at $979,290,000 after buying an additional 5,174,944 shares during the last quarter. Vanguard Group Inc. lifted its stake in Becton, Dickinson and Company by 13.0% in the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier's stock valued at $7,118,282,000 after buying an additional 4,223,149 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in Becton, Dickinson and Company by 23,219.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier's stock valued at $769,397,000 after buying an additional 4,137,888 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at about $734,321,000. Hedge funds and other institutional investors own 86.97% of the company's stock.
Analyst Ratings Changes
BDX has been the subject of several recent analyst reports. JPMorgan Chase & Co. decreased their target price on Becton, Dickinson and Company from $190.00 to $175.00 and set a "neutral" rating for the company in a research note on Tuesday, February 10th. TD Cowen reduced their price target on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a "hold" rating for the company in a research report on Monday, May 4th. Wells Fargo & Company boosted their price target on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an "equal weight" rating in a research report on Friday, May 8th. Argus reduced their price target on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a "buy" rating for the company in a research report on Monday, March 23rd. Finally, Piper Sandler reduced their price target on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a "neutral" rating for the company in a research report on Friday, April 17th. Seven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of "Hold" and an average target price of $183.64.
View Our Latest Report on Becton, Dickinson and Company
Becton, Dickinson and Company Company Profile
(
Get Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
